Triggering Transcription: Seemingly Inactive Genes are On, but 'Stuck in Neutral'
This article was originally published in Start Up
Interest in gene regulatory networks is white hot, encompassing topics as wide ranging as reprogramming skin cells to give them characteristics of embryonic stem cells to the successful development of HDAC inhibitors. Now a research team has shown that many important regulatory genes in adult cells aren't switched off, as had been believed. They're primed to make protein, but something is stopping transcription--possibly a set of master signals that could be modulated with small molecules.
You may also be interested in...
Inhibitors of histone deacetylases have been developed as cancer drugs, with only limited use because of toxicities. Now, a research team has shown that HDAC2 impairs memory and learning, suggesting that inhibitors targeting only that molecule could be used to treat neurodegenerative diseases. Buoyed by these new observations, companies with HDAC inhibitors in hand can screen their libraries specifically for activity against this newly-understood target.
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.
Recent M&A activity may have led to fewer top ranking UK biotech firms, but far from weakening the sector, it's actually providing opportunities for a newer generation of companies. Chroma Therapeutics Ltd. provides a good illustration of how experienced UK management talent is moving to lead younger, often private firms.